As of Aug 23
| -0.20 / -2.57%|
The 3 analysts offering 12-month price forecasts for InVivo Therapeutics Holdings Corp have a median target of 23.25, with a high estimate of 25.00 and a low estimate of 13.00. The median estimate represents a +207.13% increase from the last price of 7.57.
The current consensus among 3 polled investment analysts is to Buy stock in InVivo Therapeutics Holdings Corp. This rating has held steady since August, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.